Acadian Asset Management
SAGE

Acadian Asset Management’s Sage Therapeutics SAGE Stock Holding History

Acadian Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,585,415
Closed -$8.6M – 1791
2024
Q4 		$8.6M Buy
1,585,415
+638,575
+67% +$3.9M 0.03% 395
2024
Q3 		$6.83M Buy
946,840
+946,254
+161,477% +$8.66M 0.02% 418
2024
Q2 		$6K Buy
+586
New +$7.51K ﹤0.01% 1714
2022
Q2 		– Sell
-180,979
Closed -$5.99M – 1829
2022
Q1 		$5.99M Sell
180,979
-276,601
-60% -$10.4M 0.02% 426
2021
Q4 		$19.5M Buy
457,580
+78,335
+21% +$3.28M 0.07% 210
2021
Q3 		$16.8M Buy
379,245
+177,102
+88% +$8.12M 0.06% 230
2021
Q2 		$11.5M Buy
202,143
+109,093
+117% +$7.71M 0.04% 302
2021
Q1 		$6.96M Buy
93,050
+92,691
+25,819% +$7.6M 0.03% 395
2020
Q4 		$31K Buy
+359
New +$26.5K ﹤0.01% 2061
2020
Q3 		– Sell
-614
Closed -$26K – 2330
2020
Q2 		$26K Buy
+614
New +$22.3K ﹤0.01% 2082

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Acadian Asset Management's SAGE Position: Q1 2025 in Review

Acadian Asset Management sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 1,585,415 shares — an estimated $8.6M sold.

Acadian Asset Management first reported a position in SAGE in Q2 2020 and held it in 10 quarters. The position peaked at $19.5M in Q4 2021. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Acadian Asset Management reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Acadian Asset Management sold 1,585,415 Sage Therapeutics shares in Q1 2025, an estimated $8.6M.
  • Acadian Asset Management first reported a position in Sage Therapeutics in Q2 2020 and held it in 10 quarters.
  • Acadian Asset Management's Sage Therapeutics position peaked at $19.5M in Q4 2021.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Acadian Asset Management's 13F filing for Q1 2025, filed 21 May 2025.